Cintirorgon
产品说明书
 |
同义名 : | Lyc-55716 |
| CAS号 : | 2055536-64-4 | |
| 货号 : | A627902 | |
| 分子式 : | C27H23F6NO6S | |
| 纯度 : | 99%+ | |
| 分子量 : | 603.53 | |
| MDL号 : | MFCD31544352 | |
| 存储条件： |
Pure form Sealed in dry, 2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Cintirorgon, also known as LYC-55716, is a first-in-class selective oral bioactive RORγ agonist. Cintirorgon modulates gene expression in RORγ-expressing T-lymphocyte immune cells, resulting in enhanced effector function, decreased immunosuppression, reduced tumour growth, and improved survival[1][2]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT03396497 | Non-small Cell Lung Cancer | Phase 1 | Recruiting | March 2019 | United States, Colorado ... 展开 >> Lycera Investigational Site Recruiting Aurora, Colorado, United States, 80045 United States, Michigan Lycera Investigational Site Recruiting Ann Arbor, Michigan, United States, 48109 United States, Tennessee Lycera Investigational Site Recruiting Nashville, Tennessee, United States, 37203 United States, Washington Lycera Investigational Site Recruiting Seattle, Washington, United States, 98109 收起 << |
| NCT02929862 | Cancer | Phase 1 Phase 2 | Recruiting | March 2019 | - |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.66mL 0.33mL 0.17mL |
8.28mL 1.66mL 0.83mL |
16.57mL 3.31mL 1.66mL |
